• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 425 filed by Star Equity Holdings Inc.

    7/22/25 4:29:21 PM ET
    $STRR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Get the next $STRR alert in real time by email
    425 1 d921065d425.htm 425 425
     
     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, DC 20549

     

     

    FORM 8-K

     

     

    CURRENT REPORT

    Pursuant to Section 13 or 15(d)

    of The Securities Exchange Act of 1934

    Date of Report: July 22, 2025

    (Date of earliest event reported)

     

     

    Star Equity Holdings, Inc.

    (Exact name of registrant as specified in its charter)

     

     

     

    Delaware   001-35947   33-0145723
    (State or other jurisdiction
    of incorporation)
      (Commission
    File Number)
      (IRS Employer
    Identification No.)

    53 Forest Ave, Suite 101

    Old Greenwich, CT 06870

    (Address of principal executive offices, including zip code)

    (203) 489-9500

    (Registrant’s telephone number, including area code)

    Not Applicable

    (Former name or former address, if changed since last report)

     

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

     

    ☒

    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

     

    ☐

    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

     

    ☐

    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

     

    ☐

    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class

     

    Trading
    Symbol(s)

     

    Name of each exchange
    on which registered

    Common Stock, par value $0.0001 per share   STRR   NASDAQ Global Market
    Series A Cumulative Perpetual Preferred Stock, par value $0.0001 per share   STRRP   NASDAQ Global Market
    Series C Participating Preferred Stock, par value $0.0001 per Share Purchase Rights    

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

    Emerging growth company ☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     
     


    Item 8.01.

    Other Events.

    As previously disclosed, on May 21, 2025, Star Equity Holdings, Inc., a Delaware corporation (“Star”), Hudson Global, Inc., a Delaware corporation (“Hudson”), and HSON Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Hudson (“Merger Sub”), entered into an Agreement and Plan of Merger (the “Merger Agreement”), pursuant to which, among other matters, and subject to the satisfaction or waiver of the conditions set forth in the Merger Agreement, Merger Sub will merge with and into Star, with Star continuing as the surviving corporation of the merger (the “Merger”), and a wholly owned subsidiary of Hudson.

    Subject to the terms and conditions of the Merger Agreement, upon the closing of the Merger and the other transactions contemplated by the Merger Agreement (the “Closing”), (a) any shares of Star common stock held as treasury stock or held directly by Hudson or Merger Sub (or any of their respective subsidiaries) will be canceled, retired and cease to exist, and no consideration shall be delivered in exchange therefor, (b) each then-outstanding share of Star common stock will be converted into the right to receive 0.23 shares of Hudson common stock calculated in accordance with the terms of the Merger Agreement (the “Exchange Ratio”), (c) each then-outstanding share of Star Series A preferred stock will be converted into the right to receive one (1) share of Hudson Series A preferred stock (the “Hudson Series A Preferred Stock”) in accordance with the terms of the Merger Agreement, and (d) each then-outstanding option to purchase Star common stock or restricted stock units issued by Star will be converted into an option to purchase Hudson common stock or a restricted stock unit of Hudson, as applicable, which shall entitle the holder thereof to receive shares of Hudson common stock once such options are exercised or such restricted stock units are fully vested, as applicable, in each case in such amounts and on such terms as set forth in the Merger Agreement.

    In connection with the Merger, Star agreed to call a special meeting of the holders of Star common stock to seek the approval of stockholders of the Merger Agreement and the consummation of the Merger (the “Special Meeting”). The board of directors of Star has set the date and time of the Special Meeting for 10:00 a.m. Eastern Time on August 21, 2025, to be held in person at 53 Forest Avenue, Suite 101 Old Greenwich, CT 06870.

    In furtherance thereof, pursuant to the Merger Agreement, Hudson has filed a registration statement on Form S-4 (the “Registration Statement”) to register the shares of Hudson common stock and Hudson Series A Preferred Stock issuable pursuant to the Merger Agreement, which Registration Statement includes a joint proxy statement/prospectus of Star and Hudson (the “Proxy Statement/Prospectus”) forming a part thereof and giving notice to Star stockholders of the calling of the Special Meeting. On July 22, 2025, the Registration Statement was declared effective by the United States Securities and Exchange Commission (the “SEC”). Star will begin promptly disseminating the Proxy Statement/Prospectus to stockholders by mail. The Proxy Statement/Prospectus contains additional information regarding the Special Meeting, including the full list of proposals to be voted upon and instructions for stockholders regarding how to vote their shares and participate in the Special Meeting.

    The parties have determined that (i) the exchange of a U.S. Star stockholder’s shares of Star common stock for shares of Hudson common stock and (ii) the exchange of a U.S. Star stockholder’s shares of Star Series A preferred stock for shares of Hudson Series A Preferred Stock in the Merger will each be taxable transactions for U.S. federal income tax purposes. For additional details, stockholders should consult the section of the Proxy Statement/Prospectus titled “The Merger—Material U.S. Federal Income Tax Considerations of the Merger”.

    Forward-Looking Statements

    This Current Report on Form 8-K contains “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, including but not limited to, express or implied statements regarding the structure, timing and completion of the


    proposed Merger; the combined company’s listing on Nasdaq after closing of the proposed Merger; expectations regarding the ownership structure of the combined company; and other statements that are not historical fact. All statements other than statements of historical fact contained in this Current Report on Form 8-K are forward-looking statements. These forward-looking statements are made as of the date they were first issued, and were based on the then-current expectations, estimates, forecasts, and projections, as well as the beliefs and assumptions of management. There can be no assurance that future developments affecting Star, Hudson, or the proposed transaction will be those that have been anticipated.

    Forward-looking statements are subject to a number of risks and uncertainties, many of which involve factors or circumstances that are beyond Star’s control. Star’s actual results could differ materially from those stated or implied in forward-looking statements due to a number of factors, including but not limited to (i) the risk that the conditions to the closing of the proposed Merger are not satisfied, including the failure to timely obtain stockholder approval for the transaction, if at all; (ii) uncertainties as to the timing of the consummation of the proposed Merger and the ability of each of Star and Hudson to consummate the proposed Merger; (iii) risks related to Star’s ability to manage its operating expenses and its expenses associated with the proposed Merger pending closing; (iv) risks related to the failure or delay in obtaining required approvals from any governmental or quasi-governmental entity necessary to consummate the proposed Merger; (v) risks related to the market price of Star’s common stock relative to the value suggested by the exchange ratio; (vi) unexpected costs, charges or expenses resulting from the transaction; (vii) potential adverse reactions or changes to business relationships resulting from the announcement or completion of the proposed Merger; (viii) risks related to the inability of the combined company to successfully operate as a combined business; and (ix) risks associated with the possible failure to realize certain anticipated benefits of the proposed Merger, including with respect to future financial and operating results, among others. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties. These and other risks and uncertainties are more fully described in periodic filings with the SEC, including the factors described in the section titled “Risk Factors” in Star’s Annual Report on Form 10-K for the year ended December 31, 2024 filed with the SEC, and in other filings that Star makes and will make with the SEC in connection with the proposed Merger, including the Proxy Statement/Prospectus. You should not place undue reliance on these forward-looking statements, which are made only as of the date hereof or as of the dates indicated in the forward-looking statements. Star expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based. This Current Report on Form 8-K does not purport to summarize all of the conditions, risks and other attributes of an investment in Star or Hudson.

    Participants in the Solicitation

    Star, Hudson, and their respective directors and certain of their executive officers and employees may be considered participants in the solicitation of proxies from Star’s stockholders with respect to the proposed merger transaction under the rules of the SEC. Information about the directors and executive officers of Hudson is set forth in its Annual Report on Form 10-K for the year ended December 31, 2024, which was filed with the SEC on March 14, 2025, and in subsequent documents filed with the SEC. Information about Star’s directors and officers is available in Star’s Annual Report on Form 10-K for the year ended December 31, 2024, filed with the SEC on March 21, 2025, and in subsequent documents filed with the SEC. Additional information has been made available to you regarding the persons who may be deemed participants in the proxy solicitations and their direct and indirect interests (by security holdings or otherwise) in the Merger in the Registration Statement filed with the SEC, which contains the Proxy/Statement Prospectus which will be disseminated to stockholders. Instructions on how to obtain free copies of this document and, the Registration Statement and Proxy Statement/Prospectus, are set forth below in the section headed “Additional Information and Where to Find It”.

    This Current Report on Form 8-K relates to the proposed merger transaction involving Star and Hudson and may be deemed to be solicitation material in respect of the proposed merger transaction. In connection with the proposed merger transaction, Hudson has filed the Registration Statement and will promptly file the definitive Proxy Statement/Prospectus. This Current Report on Form 8-K is not a substitute for the Registration Statement, the Proxy Statement/Prospectus or for any other document that Star or Hudson may file with the SEC and or send to


    its stockholders in connection with the proposed merger transaction. BEFORE MAKING ANY VOTING DECISION, INVESTORS AND SECURITY HOLDERS OF STAR ARE URGED TO READ THE REGISTRATION STATEMENT, THE PROXY STATEMENT/PROSPECTUS AND OTHER DOCUMENTS FILED WITH THE SEC CAREFULLY AND IN THEIR ENTIRETY WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT STAR, THE PROPOSED MERGER TRANSACTION AND RELATED MATTERS.

    No Offer or Solicitation

    This Current Report on Form 8-K does not constitute an offer to sell or the solicitation of an offer to buy any securities nor a solicitation of any vote or approval with respect to the proposed transaction or otherwise. No offering of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the U S. Securities Act of 1933, as amended, and otherwise in accordance with applicable law.

    Additional Information and Where to Find It

    Investors and security holders will be able to obtain free copies of the Registration Statement, the Proxy Statement/Prospectus and other documents filed by Star or Hudson with the SEC through the website maintained by the SEC at http://www.sec.gov. Copies of the documents filed by Star with the SEC will also be available free of charge on Star’s website at https://www.starequity.com/. You may obtain free copies of this document as described above.


    SIGNATURES

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

      Star Equity Holdings, Inc.
    By:  

    /s/ RICHARD K. COLEMAN JR.

     

    Richard K. Coleman Jr.

    Chief Executive Officer

    Date: July 22, 2025

    Get the next $STRR alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $STRR

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $STRR
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Star Equity Holdings, Inc. Announces 2025 Second Quarter Financial Results

    Q2 2025 revenues increased ~76% to $23.7 million and gross profit increased ~182% to $6.3 million Generated Adjusted EBITDA of $7.0 million Quarter-end Building Solutions backlog stands at $25.7 million OLD GREENWICH, Conn., Aug. 13, 2025 (GLOBE NEWSWIRE) -- Star Equity Holdings, Inc. (NASDAQ:STRR, STRRP)) ("Star" or the "Company"), a diversified holding company, reported today its financial results for the second quarter (Q2) ended June 30, 2025. All 2025 and 2024 amounts in this release are unaudited. Q2 2025 Financial Highlights vs. Q2 2024 (unaudited) Revenues increased by 75.8% to $23.7 million from $13.5 million.Gross profit increased by 182.2% to $6.3 million from $2.2 million.

    8/13/25 8:30:29 AM ET
    $HSON
    $STRR
    Professional Services
    Consumer Discretionary
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Star Equity Holdings, Inc. Declares a Partial Cash Dividend of $0.225 Per Share of 10% Series A Cumulative Perpetual Preferred Stock

    OLD GREENWICH, Conn., Aug. 08, 2025 (GLOBE NEWSWIRE) -- Star Equity Holdings, Inc. (NASDAQ:STRR, STRRP)) ("Star" or the "Company"), a diversified holding company, announced today that its Board of Directors declared a partial cash dividend to holders of the Company's 10% Series A Cumulative Perpetual Preferred Stock ("Star Preferred Stock") of $0.225 per share. The record date for this dividend is August 21, 2025 and the payment date is September 10, 2025. As previously disclosed, on May 21, 2025, Hudson Global, Inc., a Delaware corporation ("Hudson"), HSON Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Hudson ("Merger Sub"), and the Company, entered into

    8/8/25 5:15:31 PM ET
    $STRR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Hudson Global Reports 2025 Second Quarter Results

    OLD GREENWICH, Conn., Aug. 08, 2025 (GLOBE NEWSWIRE) -- Hudson Global, Inc. (NASDAQ:HSON) ("Hudson Global" or "the Company"), a leading global total talent solutions company, announced today financial results for the second quarter ended June 30, 2025. 2025 Second Quarter Summary Revenue of $35.5 million decreased 0.5% from the second quarter of 2024 and 0.2% in constant currency.Adjusted net revenue of $18.6 million increased 5.8% from the second quarter of 2024 and 5.1% in constant currency.Net loss was $0.7 million, or $0.23 per diluted share, compared to net loss of $0.4 million, or $0.15 per diluted share, for the second quarter of 2024. Adjusted net income per d

    8/8/25 8:30:45 AM ET
    $HSON
    $STRR
    Professional Services
    Consumer Discretionary
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $STRR
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Executive Officer Coleman Richard Kenneth Jr. bought $10,675 worth of shares (2,500 units at $4.27) and bought $4,925 worth of 10% Series A Cumulative Perpetual Preferred Stock (500 units at $9.85), decreasing direct ownership by 93% to 2,500 units (SEC Form 4)

    4 - STAR EQUITY HOLDINGS, INC. (0000707388) (Issuer)

    8/20/24 4:10:35 PM ET
    $STRR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Butcher Thatcher bought $3,120 worth of shares (3,000 units at $1.04), increasing direct ownership by 100% to 6,000 units (SEC Form 4)

    4 - STAR EQUITY HOLDINGS, INC. (0000707388) (Issuer)

    12/15/23 1:41:36 PM ET
    $STRR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Coleman Richard Kenneth Jr. bought $2,220 worth of shares (2,000 units at $1.11) and bought $18,900 worth of 10% Series A Cumulative Perpetual Preferred Stock (2,000 units at $9.45), decreasing direct ownership by 98% to 2,000 units (SEC Form 4)

    4 - STAR EQUITY HOLDINGS, INC. (0000707388) (Issuer)

    12/4/23 8:25:38 PM ET
    $STRR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $STRR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Director Palmer Jennifer

    4 - STAR EQUITY HOLDINGS, INC. (0000707388) (Issuer)

    8/18/25 7:24:27 PM ET
    $STRR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form 4 filed by Director Fruhbeis Todd Michael

    4 - STAR EQUITY HOLDINGS, INC. (0000707388) (Issuer)

    8/18/25 7:23:28 PM ET
    $STRR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form 4 filed by Director Parks Louis A.

    4 - STAR EQUITY HOLDINGS, INC. (0000707388) (Issuer)

    8/18/25 7:22:47 PM ET
    $STRR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $STRR
    SEC Filings

    View All

    Star Equity Holdings Inc. filed SEC Form 8-K: Other Events

    8-K - STAR EQUITY HOLDINGS, INC. (0000707388) (Filer)

    8/15/25 4:10:33 PM ET
    $STRR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form 10-Q filed by Star Equity Holdings Inc.

    10-Q - STAR EQUITY HOLDINGS, INC. (0000707388) (Filer)

    8/13/25 4:12:57 PM ET
    $STRR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Star Equity Holdings Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - STAR EQUITY HOLDINGS, INC. (0000707388) (Filer)

    8/13/25 8:44:18 AM ET
    $STRR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $STRR
    Financials

    Live finance-specific insights

    View All

    Star Equity Holdings, Inc. Announces 2025 Second Quarter Financial Results

    Q2 2025 revenues increased ~76% to $23.7 million and gross profit increased ~182% to $6.3 million Generated Adjusted EBITDA of $7.0 million Quarter-end Building Solutions backlog stands at $25.7 million OLD GREENWICH, Conn., Aug. 13, 2025 (GLOBE NEWSWIRE) -- Star Equity Holdings, Inc. (NASDAQ:STRR, STRRP)) ("Star" or the "Company"), a diversified holding company, reported today its financial results for the second quarter (Q2) ended June 30, 2025. All 2025 and 2024 amounts in this release are unaudited. Q2 2025 Financial Highlights vs. Q2 2024 (unaudited) Revenues increased by 75.8% to $23.7 million from $13.5 million.Gross profit increased by 182.2% to $6.3 million from $2.2 million.

    8/13/25 8:30:29 AM ET
    $HSON
    $STRR
    Professional Services
    Consumer Discretionary
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Hudson Global Reports 2025 Second Quarter Results

    OLD GREENWICH, Conn., Aug. 08, 2025 (GLOBE NEWSWIRE) -- Hudson Global, Inc. (NASDAQ:HSON) ("Hudson Global" or "the Company"), a leading global total talent solutions company, announced today financial results for the second quarter ended June 30, 2025. 2025 Second Quarter Summary Revenue of $35.5 million decreased 0.5% from the second quarter of 2024 and 0.2% in constant currency.Adjusted net revenue of $18.6 million increased 5.8% from the second quarter of 2024 and 5.1% in constant currency.Net loss was $0.7 million, or $0.23 per diluted share, compared to net loss of $0.4 million, or $0.15 per diluted share, for the second quarter of 2024. Adjusted net income per d

    8/8/25 8:30:45 AM ET
    $HSON
    $STRR
    Professional Services
    Consumer Discretionary
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Star Equity Holdings to Release Second Quarter 2025 Financial Results on August 13

    OLD GREENWICH, Conn., Aug. 04, 2025 (GLOBE NEWSWIRE) -- Star Equity Holdings, Inc. (NASDAQ:STRR, STRRP)), ("Star Equity" or the "Company"), a diversified holding company, announced today that it will release its financial results for the second quarter ended June 30, 2025, before the market opens on Wednesday, August 13, 2025. A conference call is scheduled for 10:00 a.m. ET (7:00 a.m. PT) on August 13, 2025, to discuss the results and management's outlook. The call may be accessed by dialing: Toll Free: 1-833-630-1956International: 1-412-317-1837 A simultaneous webcast of the call may be accessed online from the Events & Presentations link, on the Investor Relations page of the Star Eq

    8/4/25 8:30:30 AM ET
    $STRR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $STRR
    Leadership Updates

    Live Leadership Updates

    View All

    Star Equity Holdings, Inc. Appoints Rick Coleman as CEO

    OLD GREENWICH, Conn., April 01, 2022 (GLOBE NEWSWIRE) -- Star Equity Holdings, Inc. (NASDAQ:STRR, STRRP))) ("Star Equity" or the "Company"), a diversified holding company, announced today the appointment of Richard ("Rick") K. Coleman, Jr. as Chief Executive Officer, effective April 1, 2022. In addition, Mr. Coleman will be nominated to serve as a director at the Company's upcoming annual meeting of shareholders. Mr. Coleman is a seasoned executive who brings to Star Equity extensive CEO leadership and board-level experience with numerous public and private companies. He was appointed as Star Equity's Chief Operating Officer in January 2022 and has provided valuable insights and direction

    4/1/22 8:00:00 AM ET
    $STRR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Star Equity Holdings, Inc. Adds Richard Coleman as Chief Operating Officer

    OLD GREENWICH, Conn., Dec. 20, 2021 (GLOBE NEWSWIRE) -- Star Equity Holdings, Inc. (NASDAQ:STRR, STRRP))) ("Star Equity" or the "Company"), a diversified holding company, announced today the appointment of Richard K. Coleman, Jr. ("Rick") as Chief Operating Officer, effective January 1, 2022. Coleman's addition increases the capacity of Star Equity's senior leadership team. In this role, he will oversee the Company's operations, assist its business leaders in achieving their growth and profitability goals, launch new business initiatives, as well as help analyze and integrate future acquisitions. Coleman brings more than 30 years of executive leadership experience with extensive expertis

    12/20/21 8:00:00 AM ET
    $STRR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Star Equity Holdings, Inc. Appoints John Gildea to its Board of Directors

    OLD GREENWICH, Conn., Aug. 06, 2021 (GLOBE NEWSWIRE) -- Star Equity Holdings, Inc. (NASDAQ:STRR, STRRP))) ("Star Equity" or the "Company"), a diversified, multi-industry holding company with three business divisions, Healthcare, Construction, and Investments, announced today the appointment of John W. Gildea to its Board of Directors, effective immediately. Mr. Gildea's appointment as independent director expands Star Equity's Board to six members. Mr. Gildea will also serve on the Audit Committee. Mr. Gildea brings over three decades of experience investing in special situation debt and equity of small to middle market companies. He is the founding partner of Gildea Management Co., a fir

    8/6/21 4:38:13 PM ET
    $STRR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $STRR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Star Equity Holdings Inc.

    SC 13D/A - STAR EQUITY HOLDINGS, INC. (0000707388) (Subject)

    9/10/24 4:04:39 PM ET
    $STRR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form SC 13D/A filed by Star Equity Holdings Inc. (Amendment)

    SC 13D/A - STAR EQUITY HOLDINGS, INC. (0000707388) (Subject)

    9/18/23 4:05:02 PM ET
    $STRR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form SC 13D/A filed by Star Equity Holdings Inc. (Amendment)

    SC 13D/A - STAR EQUITY HOLDINGS, INC. (0000707388) (Subject)

    8/31/23 5:18:25 PM ET
    $STRR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care